This evidence supports the growing interest in ultrasonic wave-based treatments to fight against AD brain pathology, not only by blocking or reversing Aβ and/or Tau pathology but also by attenuating inflammation, neuronal and synaptic loss, and altered brain activity. The gene discussed is MAPT; the disease is Alzheimer disease.